A meta-analysis by Lukashchuk and colleagues found that advanced, metastatic prostate cancers show significantly increased rates of mutation in homologous recombination repair enzymes, including BRCA1/2, than primary prostate cancers [221]. This evidence concerns the gene BRCA1 and Familial prostate cancer.